Cargando…

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

BACKGROUND & AIMS: Functional cure of chronic HBV infection (CHB) without life-long treatment requires the restoration of defective HBV-specific humoral and cellular immunity. Therapeutic vaccines based on the major structural and non-structural proteins have been tested in patients with CHB but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Haiyan, Lim, Tien Huey, Leerapun, Apinya, Weltman, Martin, Jia, Jidong, Lim, Young-suk, Tangkijvanich, Pisit, Sukeepaisarnjaroen, Wattana, Ji, Yun, Le Bert, Nina, Li, Dong, Zhang, Yao, Hamatake, Robert, Tan, Nicole, Li, Chunming, Strasser, Simone I., Ding, Huiguo, Yoon, Jung-Hwan, Stace, Nigel H., Ahmed, Tanvir, Anderson, Dave E., Yan, Li, Bertoletti, Antonio, Zhu, Qing, Yuen, Man-Fung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502773/ https://www.ncbi.nlm.nih.gov/pubmed/34661089 http://dx.doi.org/10.1016/j.jhepr.2021.100361

Ejemplares similares

HBV-HCC treatment with mRNA electroporated HBV-TCR T cells
por: Tan, Anthony T, et al.
Publicado: (2021)

Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients
por: Sripongpun, Pimsiri, et al.
Publicado: (2019)

HBV-Specific Adaptive Immunity
por: Bertoletti, Antonio, et al.
Publicado: (2009)

520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants
por: Margolis, David A, et al.
Publicado: (2021)

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
por: Lim, Young-Suk
Publicado: (2023)

Genetic associations of vitamin D receptor polymorphisms with advanced liver fibrosis and response to pegylated interferon-based therapy in chronic hepatitis C
por: Thanapirom, Kessarin, et al.
Publicado: (2019)

Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
por: Hao, Xiaohua, et al.
Publicado: (2022)

Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection
por: Thanapirom, Kessarin, et al.
Publicado: (2015)

Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients
por: Thanapirom, Kessarin, et al.
Publicado: (2017)

T cell receptor-therapy in HBV-related hepatocellularcarcinoma
por: Bertoletti, Antonio, et al.
Publicado: (2015)

Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application
por: Hayashi, Sanae, et al.
Publicado: (2022)

Tolerance and immunity to pathogens in early life: insights from HBV infection
por: Hong, Michelle, et al.
Publicado: (2017)

Fine‐Tuning TLR‐7‐Based Therapy for Functional HBV Cure
por: Bertoletti, Antonio, et al.
Publicado: (2019)

An unusual renal manifestation of chronic HBV infection
por: Aravindan, Ananthakrishnapuram, et al.
Publicado: (2010)

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)

Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions
por: Healy, Katie, et al.
Publicado: (2021)

S gene mutations of HBV in children with HBV-associated glomerulonephritis
por: Lu, Hongzhu, et al.
Publicado: (2012)

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Publicado: (2022)

Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCC
por: Tan, Anthony Tanoto, et al.
Publicado: (2021)

High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Trained immunity in newborn infants of HBV-infected mothers
por: Hong, Michelle, et al.
Publicado: (2015)

MicroRNAs Associated With HBV Infection And HBV-related HCC
por: Xie, Kun-Lin, et al.
Publicado: (2014)

HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
por: Liu, Shousheng, et al.
Publicado: (2019)

Monitoring the emergence of HBV resistance mutations by HBV-RNA pyrosequencing
por: Bottecchia, Marcelle, et al.
Publicado: (2015)

Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation
por: Bertoletti, Antonio, et al.
Publicado: (2014)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients
por: Liu, Xin, et al.
Publicado: (2023)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
por: Gozlan, Yael, et al.
Publicado: (2022)

Cytokines and Chemokines in HBV Infection
por: Zhong, Shihong, et al.
Publicado: (2021)

The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma
por: Zhang, Cunzhen, et al.
Publicado: (2022)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity
por: Yuan, Si-Yu, et al.
Publicado: (2022)

High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable
por: Wang, Chengwei, et al.
Publicado: (2023)

HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas
por: Yang, Ming, et al.
Publicado: (2020)

Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model
por: Kan, Fangming, et al.
Publicado: (2017)

Acute‐on‐chronic liver failure: Epidemiology, prognosis, and outcome of a multicenter study in Thai population
por: Chirapongsathorn, Sakkarin, et al.
Publicado: (2022)

Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study
por: Teerasarntipan, Tongluk, et al.
Publicado: (2022)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Pharmacokinetics of Anti-HBV Polyoxometalate in Rats
por: Wang, Juan, et al.
Publicado: (2014)

Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment
por: Zhang, Dake, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6q13fqesm08aco66uh0qiaos83